

COMPLETE IF KNOWN					
Application Number	10/588,883				
Confirmation Number	4457	Ī			
Filing Date	May 8, 2007	1			
First Named Inventor	Jinhua An et al.	_			
Group Art Unit	1625	_			
Examiner Name	Mabry, John				
Attorney Docket No.	62497-8004 US00 (57070-8017 US00)	Ξ			

			U	I.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.		on d Code known)	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
	1.	US-2002/0077350	A1	Babish et al.	06-20-2002	
	2.	US-2002/0099051	A1	Fidler et al.	07-25-2002	
	3.	US-2004/0152767	A1	Dai et al.	08-05-2004	
	4.	US-2004/0198808	A1	Dai et al.	10-07-2004	
	5.	US-2004/0235943	A1	Dai et al.	11-25-2004	
	6.	US-2005/2883645	A1	LaVon	12-29-2005	
	7.	US-2007/0244080	A1	Fidler et al.	10-18-2007	
	8.	US-2007/0249048	A1	Dai et al.	10-25-2007	
	9.	US-2007/0282114	A1	An et al.	12-06-2007	
	10.	US-2008/0287530	A1	Yuan et al.	11-20-2008	
	11.	US-5,294,443		Lipsky et al.	03-15-1994	
	12.	US-5,919,816		Hausheer et al.	07-06-1999	
	13.	US-5,972,998		Jung et al.	10-26-1999	
	14.	US-6,004,999		Jung et al.	12-21-1999	
	15.	US-6,011,042		Greenwald et al.	01-04-2000	
	16.	US-6,103,875		Martinez-Miller et al.	08-15-2000	
	17.	US-6,329,148	B1	Rosen et al.	12-11-2001	
	18.	US-6,458,537		Staub et al.	10-01-2002	
	19.	US-6,777,441		Wang et al.	08-17-2004	
	20.	US-6,943,259	B2	Dai et al.	09-13-2005	
	21.	US-7,019,151	B2	Dai et al.	03-28-2006	
	22.	US-7,098,348	B2	Dai et al.	08-29-2006	
	23.	US-7.417.069	B2	Dai et al.	08-26-2008	

10

EXAMINER	DATE CONSIDERED
/John Mabry/ (04/23/2010)	
*EXAMINER: Initial if reference considered, whether or not criteria is in co	Informance with MPEP 609. Draw line through citation if not in

					COMPLETE IF KNOWN
•				Application Number	10/588,883
INFORMATION DISCLOSURE				Confirmation Number	4457
STATEMENT BY APPLICANT				Filing Date	May 8, 2007
		449 (Modified)	,	First Named Inventor	Jinhua An et al.
	(Use several sh	eets if necessary)		Group Art Unit	1625
				Examiner Name	Mabry, John
Sheet	2	of	10	Attomey Docket No.	62497-8004.US00 (57070-8017.US00)

				FORE	GN PATENT DOCUMENTS			
Examiner Initial	Cite No.	Office	oreign Patent or Application	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	т
	24.	CN	CN 1052859	Α	Skin Disease Inst. Chinese Acad. (CN) (English Abstract only)	07-10-1991		1
	25.	EPO	EP 0 156 643	B1	The Upjohn Company	10-02-1985		
	26.	JPO	03 178977		Chugoku Igaku Kagak (English Abstract Only)	08-11-1991		1
	27.	PCT	WO 94/26265	A1	Pharmagenesis, Inc.	11-24-1994		
	28.	PCT	WO 98/52933	A1	Hoechst Marion Roussel Inc.	11-26-1998		
	29.	PCT	WO 98/52951	A1	Hoechst Marion Roussel Inc.	11-26-1998		
	30.	PCT	WO 00/12483	A1	Pharmagenesis, Inc.	03-09-2000		
	31.	PCT	WO 00/63212		Chengdu Diao Pharmaceutical group Company Limited	10-26-2000		
	32.	PCT	WO 02/070472	A1	Pharmagenesis, Inc.	09-12-2002		
	33.	PCT	WO 02/074759	A1	Pharmagenesis, Inc.	09-26-2002		
	34.	PCT	WO 03/101951	A2	Pharmagenesis Inc.	12-11-2003		
	35.	PCT	WO 05/000291	A1	Pharmagenesis, Inc.	01-06-2005		
	36.	PCT	WO 05/020887	A2	Pharmagenesis, Inc.	03-10-2005		
	37.	PCT	WO 05/062913	A2	Pharmagenesis Inc.	07-14-2005		
	38.	PCT	WO 05/084365	A2	Pharmagenesis Inc.	09-15-2005		
	39.	PCT	WO 06/012204	A2	Pharmagenesis Inc.	02-02-2006		

EXAMINER	/John Mabry/ (04/23/2010)	DATE CONSIDERED
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance and not considered. Include copy of this form	onformance with MPEP 609. Draw line through citation if not in

				(	COMPLETE IF KNOWN
•				Application Number	10/588,883
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Confirmation Number	4457
				Filing Date	May 8, 2007
	Form PTO-1449 (Modified)			First Named Inventor	Jinhua An et al.
	(Use several shi	eets if necessary)		Group Art Unit	1625
				Examiner Name	Mabry, John
Sheet	3	of	10	Attorney Docket No.	62497-8004.US00 (57070-8017.US00)

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposine, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	_
		Anderson, Wayne K. et al., "Synthesis, Evaluation of Chemical Reactivity, and Murine Antineoplastic Activity of 2-Hydroxy-5-(3,4-dichlorophenyl)-6,7-bis(hydroxymethyl)-2,3-	
	40.	dihydro-1 <i>H</i> -pyrrolizine Bis(2-propylcarbamate) and 2-Acyloxy Derivatives as Potential Water-Soluble Prodrugs <sup>1</sup> ", <i>J. Med. Chem.</i> , <u>26</u> :1333-1338 (1983).	
	41.	AUMULLER, G. et al., "Intermediate filaments in sertoli cells", Microscopy Research and Technique, 20:50-72(1992).	
	42.	BECKER, K. et al., "Thioredoxin reductase as a pathophysiological factor and drug target", Eur. J. Biochem., 267(20):6118-6125 (2000).	
	43.	BERG, D. et al., "14-3-3 Proteins in the nervous system", Nature Reviews Neuroscience, 4:752-62 (2003).	
	44.	BRITTON, R. et al., "New okadaic acid analogues from the marine sponge Merriamum oxeato and their effect on mitosis", J. Nat. Prod., 66:838-43 (2003).	
	45.	CHANG, W-T. et al., "Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway", <i>The Journal of Biological Chemistry"</i> , <u>276(3)</u> :2221-2227 (2001).	
	46.	CHEN et al., "Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model", <i>Transplantation</i> , 73(1):115 (2002).	
	47.	CHEN et al., "Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion", <i>Transplantation</i> , 70(10):1442-1447 (2000).	
	48.	CHENG, X.X. et al., Yao Xue Xue Bao, ACTA Pharmaceutica Sinica, 37:339-342 (2002) (English Abstract translation).	1
	49.	DAN et al., "Studies on triepoxide analogs of triptolide", <i>Tetrahedron Letters</i> , 38(39):6865-6868 (1997).	
	50.	DE GROOT Franciscus M. H. et al., "Synthesis and Biological Evaluation of 2'-Carbamate-Linked and 2'-Carbonate-Linked Prodrugs of Paclitaxel: Selective Activation by the Tumor-Associated Protease Plasmin", <i>J. Med. Chem.</i> , 43:3093-3102 (2000).	
3	51.	DE QUAN Yu et al., "Chemical Transformation of Triptolide", Chinese Chemical Letters, 2(12):937-940 (1991).	
	52.	DITTERT, L.W. et al., "Acetaminophen Prodrugs I Synthesis, Physicochemical Properties, and Analgesic Activity", <i>Journal of Pharmaceutical Sciences</i> , <u>57</u> (5):774-780 (1968).	

EXAMINER	/John Mabry/ (04/23/2010)	DATE CONSIDERED
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance and not considered. Include copy of this form	informance with MPEP 609. Draw line through citation if not in with next communication to application(s).

				0	COMPLETE IF KNOWN		
•				Application Number	10/588,883		
INFORMATION DISCLOSURE				Confirmation Number	4457		
STATEMENT BY APPLICANT				Filing Date	May 8, 2007		
		449 (Modified)		First Named Inventor	Jinhua An et al.		
(	Use several she	eets if necessary)		Group Art Unit	1625		
				Examiner Name	Mabry, John		
heet	4	of	10	Attomey Docket No.	62497-8004.US00 (57070-8017.US00)		

	53.	DITTERT, L.W. et al., "Acetaminophen Prodrugs II Effect of Structure and Enzyme Source on Enzymatic and Nonenzymatic Hydrolysis of Carbonate Esters", <i>Journal of Pharmaceutical Sciences</i> , 57(5):780-783 (1968).	
	54.	ENGLEBIENNE et al., <u>Drug Design Reviews -Online</u> , "The Place of Biosteric Sila Substitution in Drug Design", 2 pages (2005).	
	55.	FIDLER, J.M. et al., "PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy", Molecular Cancer Therapeutics, 2(9):855-62 (2003).	
	56.	FIDLER, J.M. et al., "Immunosuppressive activity of the Chinese medicinal plant Tripterygium wilfordii. III. Suppression of graft-versus-host disease in murine allogeneic bone marrow transplantation by the PG27 extract", <i>Transplantation</i> , 74(4):445-457 (2002).	
	57.	FRUMAN, D.A. et al., "Phosphoinositide Kinases", Ann. Rev. Biochem., <u>67</u> :481-507 (1998).	
	58.	FU et al., "14-3-3 Proteins: Structure, Function, and regulation", Ann. Rev. Pharmacol. Toxicol., 40:617-47 (2000).	
	59.	GABBIANI, G., "The myofibroblast in wound healing and fibrocontractive diseases", Journal of Pathology, 200:500-503 (2003).	
	60.	GARCIA, A. et al., "Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis", <i>Biochimie</i> , 85:721-726 (2003).	
	61.	GILLES, C. et al., "Transactivation of vimentin by beta-catenin in human breast cancer cells", Cancer Research, 63(10):2658-2664 (2003).	
	62.	GLEICHMANN, E. et al., "Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases", <i>Immunology Today</i> , 5(11):324-332 (1984).	
	63.	GOTO, Y. et al., "Augmented cytoplasmic Smad4 induces acceleration of TGF-beta1 signaling in renal tubulointerstitial cells of hereditary nephrotic ICGN mice with chronic renal fibrosis; possible role for myofibroblastic differentiation", Cell Tissue Res., 315:209-221 (2004).	
	64.	GROSS, T.J. and Hunninghake, G.W., "Idiopathic pulmonary fibrosis", N. Engl. J. Med., 345(7):517–525 (2001).	
,	65.	HANSEN, Kristian T. et al., "Carbamate Ester Prodrus of Dopaminergic Compounds: Synthesis, Stability, and Bioconversion", <i>Journal of Pharmaceutical Sciences</i> , 80(8):793-798 (1991).	
	66.	HANSEN, Laila B. <i>et al.</i> , "Ketobemidone prodrugs for buccal delivery", <i>Acta Pharm. Nord.</i> , 3(2):77-82 (1991).	
	67.	HE, Q. et al., "Neuroprotective eggects of <i>Tripterygium Wilfordii Hook F</i> Monomer T <sub>10</sub> on glutamate induced PC12 cell line damage and its mechanism", <i>Beijing Da Xue Xue Bao, Journal of Peking University (Health Sciences)</i> , 35(3):252-5 (Jun 2003) (English Abstract Translation).	1
EXAMINER		DATE CONSIDERED	i

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

/John Mabry/ (04/23/2010)

				COMPLETE IF KNOWN		
•				Application Number	10/588,883	
		DISCLOSURE		Confirmation Number	4457	
		BY APPLICANT		Filing Date	May 8, 2007	
Form PTO-1449 (Modified)				First Named Inventor	Jinhua An et al.	
(1	Use several she	ets if necessary)	)	Group Art Unit	1625	
				Examiner Name	Mabry, John	
Sheet	5	of	10	Attorney Docket No.	62497-8004.US00 (57070-8017.US00)	

Sheet	5 Of 10 Attorney Docket No. 62497-8004.US00 (57070-8017.US00)
68.	HOUTMAN, J.C. ET AL., "Early phosphorylation kinetics of proteins involved in proximal TCR-mediated signaling pathways", <i>Journal of Immunology</i> , <u>175</u> (4):2449-2458 (2005).
69.	HUANG, Tien L. et al., "Hydrolysis of Carbonates, Thiocarbonates, Carbamates, and Carboxylic Esters of α-Naphthol, β-Naphthol, and p-Nitrophenol by Human, Rat, and Mouse Liver Carboxylesterases", Pharmaceutical Research, 10(5):639-648 (1993).
70.	JIANG, X-H. et al., "Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells", Oncogene, 20(55):8009- 8018 (2001).
71.	JERUMS, G. et al., "Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease", Archives of Biochemistry and Biophysics, 419(1):55-62 (2003).
72.	JIARUN, Z. et al., "Screening of active anti-inflammatory, immunosuppressive and antifertility components of <i>Tripterygium Wilfordii</i> ", ACTA Academiae Medicinae Sinicae 13(6):391-397 (English Abstract only) (1991).
73.	JONES, S.L. et al. "A role for the actin-bundling protein L-plastin in the regulation of leukocyte integrin function", <i>Proc. Natl. Acad. Sci. USA</i> , 95(16):9331-9336 (1998).
74.	KAHNS, A. M. et al., "Prodrugs of Peptides. 18. Synthesis and Evaluation of Various Esters of Desmopressin (dDAVP)", Pharmaceutical Research, 10(1):68-74 (1993).
75.	KERSHENOBICH, D. et al., "Concise Review: Liver fibrosis and inflammation. A review", Annals of. Hepatology, 2(4):159-163 (2003).
76.	KEYSER, F. D. et al., "The role of T cells in Rheumatoid Arthritis", Clinical Rgeumatology, 14(Suppl 2):5-9 (1995).
77.	KHANNA, A.K. and MEHTA, M.R., "Targeted in vitro and in vivo gene transfer into T lymphocytes: potential of direct inhibition of allo-immune activation", <i>BMC Immunology</i> , 7(26):1-10 (2006).
78.	KORNGOLD, B. and SPRENT, J. "Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow", J. Exp. Med., 148:1687-98 (1978).
79.	KURZ, E.U. et al., "Modulation of human DNA topoisomerase Ilalpha function by interaction with 14-3-3epsilon", <i>The Journal of Biological Chemistry</i> , <u>275</u> (18):13948-13954 (2000).
80.	KUTNEY, J.P. et al., "Studies with plant cell cultures of the Chinese herbal plant, Tripterygium Wilfordii, Synthesis and biotransformation of diterpene analogues", Heterocycles, 44(1):2-11 (1997).
81.	LARRIBERE, L. et al., "PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes". Cell Death and Differentiation. 11(10):1084-1091 (2004).

EXAMINER	/John Mabry/ (04/23/2010)	DATE CONSIDERED
*EXAMINER:	Initial if reference considered, whether or not criteria is in co conformance and not considered. Include copy of this form	nformance with MPEP 609. Draw line through citation if not in with next communication to application(s).

					COMPLETE IF KNOWN	
				Application Number	10/588,883	
INFORMATION DISCLOSURE				Confirmation Number	4457	
		BY APPLICANT		Filing Date	May 8, 2007	
		449 (Modified)		First Named Inventor	Jinhua An et al.	
	(Use several she	eets if necessary	)	Group Art Unit	1625	
				Examiner Name	Mabry, John	
Sheet	6	of	10	Attomey Docket No.	62497-8004.US00 (57070-8017.US00)	
	LEONARD	, C.T. et al., "	PG490-88	a derivative of trip	tolide, attenuates obliterative	
82. airway disease in a mouse heterotopic tracheal allograft model". Journal of Heart and						

	82.		derivative of triptolide, attenuates obliterative c tracheal allograft model", <i>Journal of Heart and</i>	
	<b>0</b>	Lung Transplantation, 21(12):1314-13		
	83.	LEUENROTH, S.J. and CREWS, C.N	I., "Studies on calcium dependence reveal multiple stry and Biology, 12(12):1259-1268 (2005).	
	84.		8 erxerts 1-16 potent anticancer activity alone and	_
	84.	in combination therapy in a nude mou	se xenograft model", Proceedings of the	
		American Association for Cancer Res	earch Annual Meeting March 2001,	
		42:73, Abstract #391 (2001)		<u> </u>
	0.5		oprotective effects of tripchlorolide, an extract of	
	85.		ook F, on dopaminergic neurons", <i>Experimental</i>	
	_	Neurology, 179(1):28-37 (2003).	nerbal extract, protects dopaminergic neurons	$\vdash$
	86.		through inhibition of microglial activation", Journal	
	00.	of Neuroimmunology, 148(1-2):24-31		
			stin gene by testosterone in breast and prostate	_
	87.	cancer cells: identification of three co	operative androgen receptor-binding sequences",	
		DNA Cell Biology, 19(1):1-7 (2000).		ш
			growth factor receptor-1 and receptor-2 initiate a	1
	88.		dent clonogenic response in acute myeloid	ĺ
		leukemia cells.", Experimental Hemat	doxin and increased thioredoxin reductase levels in	$\vdash$
	89.		Il Biology & Medicine, <u>28</u> (3):418-27 (2000).	İ
			mutation in active site of thioredoxin increases its	Г
	90.		ew refolding systems for reduced or randomly	ĺ
			f Biological Chemistry, <u>267</u> (13):9047-9052 (1992).	_
	91.		vium in rheumatoid arthritis", Arthritis Research &	
		Therapy, 9(1):1-11 (2007).	-liddlan drug-" ACTA	⊢
	92.	MA et al., "Isolation of 17-hydroxytript Pharmaceutica Sinica, 28(2):110-115		1
			apy fir idiopathic pulmonary fibrosis", Am. J.	$\vdash$
	93.	Respir. Crit. Care Med., 160:1771-17		
			Proteins mediate an essential anti-apoptotic	一
	94.	signal", The Journal of Biological Che		
	95.		compounds from Tripterygium Wilfordi Hook F.",	Г
	95.	Contraception, 47:387-400 (1993).		L
			ative activity of the farnesyltransferase inhibitor	ĺ
	96.		s from patients with myelofibrosis with myeloid	ĺ
EXAMINER		metaplasia", <i>Leukemia</i> , <u>17</u> (5):849-55	DATE CONSIDERED	$\vdash$
LAAMINEN	/J	John Mabry/ (04/23/2010)	DATE CONCIDENCE	
		' '		1

"EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s). ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

					OND STEEL WHOMAN	1
					COMPLETE IF KNOWN	1
	NEORMATION	DISCLOSURE		Application Number	10/588,883	1
		BY APPLICANT		Confirmation Number	4457	1
		449 (Modified)		Filing Date	May 8, 2007	1
1 (		eets if necessary	٠.	First Named Inventor	Jinhua An et al.	1
,	ooc octoral on	colo il ricocobally		Group Art Unit	1625	1
Chast	7	of	10	Examiner Name	Mabry, John	1
Sheet		J OI	10	Attorney Docket No.	62497-8004.US00 (57070-8017.US00)	J
97.	triptolide or		f PC12 cells	induced by Aβ1-4	wilfordii Hook F monomer 42" ACTA Physiologica Sinica,	1
98.	antiprolifer	ative drugs",	Transplantati	on, <u>55</u> (4):701-70		
99.	Nonenzym Pharmace	atic Hydrolysi utical Science	s of Carbona s, <u>81(3):</u> 295	ate and Carbama -298 (1992).	s on the Rates of Enzymatic and te Esters", <i>Journal of</i>	
	Tetrahedro	n, <u>59</u> (23):420	9-4213 (200	3).	ninghamella blakesleana",	
101				ved technique of ular Surgery, <u>57</u> (2	heart transplantation in rats", 2):225-29 (1969).	
102	dephospho		1 and Raf-1		pulates Ras signaling by binding sites", <i>Current Biology</i> ,	
	cancer pro	gression and ations, 289(4	metastasis", ):876-881 (20	Biochemical and	lastin gene in human colorectal I Biophysical Research	
104	activation of	of mitogen-ac	tivated prote	in kinases ERK1/	tein phosphatase 2A produces (2, MEK1/2, and p70 S6, similar to hology, <u>163</u> (3):845-858 (2003).	
105				"Properties and b	piological activities of 295 (2000).	
106	QIU, D. AN triptolide, t	ID KAO, P.N.	, "Immunosu ctive diterpe	ppressive and ar noid from the Chi	nti-inflammatory mechanisms of nese medicinal herb <i>Tripterygium</i>	
107	expression transcriptio (1999).	at the level on onal activation	of purine-box ", The Journ	Inuclear factor of al of Biological C	) inhibits T-cell interleukin-2 activated T-cells and NF-kappaB hemistry, <u>274</u> (19):13443-13450	
	rapamycin-	sensitive sign	nalling pathw	ay", The EMBO	gation factor-2 by insulin via a Journal, <u>15</u> (9):2291-2297 (1996).	
109	role in cell	cycle progres	sion", Oncog	gene, <u>19</u> (4):514-5	uman carcinoma cell lines and its 525 (2000).	
110	Sci USA, 9	7(20):10832-	10837 (2000	).	binding to Hsp90 ", <i>Proc Natl Acad</i>	
111					vivo evaluation of novel oral N- e", Life Sciences, <u>67</u> :205-216	
EXAMINER	John Mabry/ (	04/23/2010)		DATE CONSIDERED		
				onformance with MPEP 6 with next communication	09. Draw line through citation if not in n to application(s).	]

					COMPLETE IF KNOWN
,				Application Number	10/588,883
	INFORMATION			Confirmation Number	4457
	STATEMENT B			Filing Date	May 8, 2007
	Form PTO-14			First Named Inventor	Jinhua An et al.
(Use several sheets if necessary)			)	Group Art Unit	1625
				Examiner Name	Mabry, John
Sheet	8	of	10	Attorney Docket No.	62497-8004.US00 (57070-8017.US00)

112	SCHLESINGER, C. et al., "Constrictive (obliterative) bronchiolitis: diagnosis, etiology, and a critical review of the literature", Annals of Diagnostics Pathology,. 2(5):321-34 (1998).
113	SCHLESINGER, C. et al., "Constrictive (obliterative) bronchiolitis ", Current Opinion in Pulmonary Medicine, 4:288-293 (1998).
114	disulfide isomerization by protein-disulfide isomerase", <i>The Journal of Biological Chemistry</i> , 278(9):7154-7159 (2003).
	SELMAN, M. et al., "Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy ", <i>Ann. Intern. Med.</i> , <u>134</u> :136-151 (2001).
116	SHAMON, L.A. et al., "Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from <i>Tripterygium willfordii</i> ", <i>Cancer Letters</i> , 112:113-117 (1997).
117	SHANMUGANATHAN et al., "Enhanced brain delivery of an anti-HIV nucleoside 2'-F-ara-ddl by xanthine oxidase mediated biotransformation", <i>J. Med. Chem.</i> , <u>37</u> :821-827 (1994).
	SHEVCHENKO, A. et al., "Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels", Anal. Chem., 68(5):850-858 (1996).
119	SHEVCHENKO, A. et al., "Linking genome and proteome by mass spectrometry: large- scale identification of yeast proteins from two dimensional gels", <i>Proc Natl Acad Sci</i> <i>USA</i> , 93:14440-14445 (1996).
120	SHOW, M. et al., "Reduced intratesticular testosterone concentration alters the polymerization state of the Sertoli cell intermediate filament cytoskeleton by degradation of vimentin", Endocrinology, 144(12):5530-6 (2003).
	SOLIT, D. et al., "Hsp90 as a therapeutic target in prostate cancer", Seminars in Oncology, 30(5):709-16 (2003).
	SONTAG <i>et al.</i> , "Protein phosphatase 2A is a critical regulator of protein kinase C zeta signaling targeted by SV40 small t to promote cell growth and NF-kappaB activation", <i>The EMBO Journal</i> , 19(18):5662-5671 (1997).
	STELLA, V.J. et al., "Prodrugs, Do they have advantages in Clinical Practice ?", <i>Drugs</i> , 29:455-473 (1985).
	TOLSTONOG et al., "Role of the intermediate filament protein vimentin in delaying senescence and in the spontaneous immortalization of mouse embryo fibroblasts", DNA and Cell Biology, 20(9):509-29(2001).
125	TUNEK, Anders <i>et al.</i> , "Hydrolysis of <sup>3</sup> H-Bambuterol, A Carbamate Prodrug of Terbutaline, in Blood from Humans and Laboratory Animals <i>In Vitro</i> ", <i>Biochemical Pharmacology</i> , <u>37</u> (20):3867-3876 (1988).

EXAMINER	/John Mabry/ (04/23/2010)	DATE CONSIDERED
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance and not considered. Include copy of this form	onformance with MPEP 609. Draw line through citation if not in with next communication to application(s).

					COMPLETE IF KNOWN
				Application Number	10/588,883
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Confirmation Number	4457
				Filing Date	May 8, 2007
	Form PTO-14			First Named Inventor	Jinhua An et al.
(U	Jse several she	ets if necessary	)	Group Art Unit	1625
				Examiner Name	Mabry, John
Sheet	9	of	10	Attorney Docket No.	62497-8004.US00 (57070-8017.US00)

Sheet	9	of	10	Attorney Docket No.	62497-8004.US00 (57070-8017.US00)	
126					of (.+, -) -triptonide and (.+) -	
			ionai Databas	se, CAPLUS data	base Document No. 96:143107 2	
127	pages (198		, fluoringtod	ananhinhilan an da	rug and gene carrier and delivery	
127				stry, <u>107</u> :337-354		
128					. Clin. Pharmac., 28:497-507	_
	(1989).			•	.—	
129	WAHLGRE	N, C-F. et al	, "Itch and inf	lammation induce	ed by intradermally injected	
	interleukin-	2 in atopic de	ermatitis patie	ents and healthy s	subjects", Arch Dermatol Res.,	
	287(6):572	-580 (1995).				
130	WANG, Z.	et al., "Altere	d distribution	of Sertoli cell vim	nentin and increased apoptosis in	
i	cryptorchid	rats", Journa	al of Pediatric	Surgery, 37(4):6	48-652 (2002).	
131	WANG, J.	<i>et al</i> ., "Immu	nosuppressiv	e activity of the C	hinese medicinal plant	
					d renal allograft survival by the	
					bination therapy with	
				:447-455 (2000).		
132					nd mono- or combination therapy	
					enolic acid and deoxyspergualin	
					edings, <u>23(</u> 1):699-702 (1991).	_
133					optosis: Effect on caspase	
				entiality of the hyd	droxyl group of triptolide", J. Mol.	
		05-415 (2006			Kinatian af hudash air af harmal	
134					Kinetics of hydrolysis of benzyl	
					solutions and human plasma",	
			:159-162 (19		duced by Tripterygium Wilfordii",	_
135					054 (2002) (No English Abstract	
	Translation		i neibai biug	3, <u>33(</u> 11).1033-10	034 (2002) (NO Eligiisti Abstract	
126			The stress re	snonse implicati	ons for the clinical development	_
130	of hsn90 in	hibitors" Cur	rent Cancer	Drug Targets, 3(5	5):349-358 (2003).	
137					icts inhibit de novo protein	_
'0'					ximal tubular cells", Kidney	
		al, 63(2):464				
138				ical Studies on wa	ater-Soluble corticosteroid	
					s in Solution", Journal of the	
				(8):855-862 (197		_
139				poptotic death of	f T lymphocyte",	
	Immunoph	armacology,	<u>40</u> :139-149 (	1998).		

EXAMINER	/John Mabry/ (04/23/2010)	DATE CONSIDERED
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance and not considered. Include copy of this form	nformance with MPEP 609. Draw line through citation if not in with next communication to application(s).

					COMPLETE IF KNOWN
INFORMATION DISCLOSURE				Application Number	10/588,883
				Confirmation Number	4457
	STATEMENT E			Filing Date	May 8, 2007
	Form PTO-14			First Named Inventor	Jinhua An et al.
(Use several sheets if necessary)			)	Group Art Unit	1625
				Examiner Name	Mabry, John
Sheet	10	of	10	Attorney Docket No.	62497-8004.US00 (57070-8017.US00)

140	Yang, J. et al., "Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin", Cancer Research, 61(10):4010-4016 (2001).
141	YANG, S. et al., "Triptolide Inhibits the Growth and Metastasis of Solid Tumors", Molecular Cancer Therapeutics, 2:65-72 (2003).
142	YANO, H. et al., "Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells", The Journal of Biological Chemistry, 268(34):25846-25856 (1993).
143	YUAN, G-H. et al., "Characterization of cells from pannus-like tissue over articular cartilage of advanced osteoarthritis", OsteoArthritis and Cartilage, 12(1):38-45 (2004).
144	ZHENG et al., "Screening of active iantiinflammatory, immunosuppressive and antifertility components of Tripterygium Wilfordii", Chemiacl Abstracts 117(9): Abstract No. 83085a (1992)
145	ZHOU, H-F. et al., "Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures", Neuroreport, 14(7):1091-5 (2003).
146	ZHOU, Y.X. et al., Ai Zheng 21:1108-8 (2002).

EXAMINER	/John Mabry/ (04/23/2010)	DATE CONSIDERED	
*EXAMINER:	*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).		